Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues
Nektar Therapeutics reported a better-than-expected loss in the
fourth quarter but lagged analysts’ expectations for revenues.
Shares of the biopharmaceutical company dropped almost 1.5% to
close at $22.44 on Feb. 25. Nektar (NKTR) incurred a loss of $0.65
per share in 4Q, compared to the $0.68 loss per share estimated by
analysts. Total sales generated in the quarter amounted to $23.5
million, falling short of analysts’ expectations of $30.01 million.
The company’s research and development expenses were $102.7 million
in the quarter, down 7% year-over-year. (See Nektar stock analysis
on TipRanks) Nektar CEO Howard W.